Anupam Rama (J.P. Morgan) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Anupam Rama's stock ratings?

About 47% of Anupam's ratings were profitable over a one-year hold, with an average return of +1.8% per rating, measured by 13Foresight from historical prices.

Q: How is Anupam ranked?

Anupam Rama is ranked #2198 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Anupam Rama

JPM

Anupam Rama

J.P. Morgan

Wall Street Analyst

★★☆☆☆

#2198

on 13Foresight · ranked by our own returns

47%

Success Rate

+1.8%

Average Return

27 of 58 calls profitable · -5.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 47% of Anupam Rama's ratings turned a profit when each position was held for 1 year — averaging +1.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

173 Buy 32 Hold 9 Sell

Anupam's Stock Coverage 54 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
CAMP CAMP4 Therapeutics Corporation	Jun 16, 2026	BUY	Strong Buy +131.6% avg upside 9 analysts	$9.00 117.93% Upside	·
NUVL Nuvalent	Jun 09, 2026	HOLD	Buy -0.3% avg upside 21 analysts	$124.00 0.48% Upside	+0.1%
OLMA Olema Pharmaceuticals	Jun 09, 2026	BUY	Strong Buy +303.4% avg upside 16 analysts	—	-12.1%
FULC Fulcrum Therapeutics	Jun 02, 2026	SELL	Hold +138.4% avg upside 13 analysts	—	·
COGT Cogent Biosciences	May 31, 2026	BUY	Strong Buy +7.1% avg upside 26 analysts	—	-1.7%
REPL Replimune Group	May 29, 2026	HOLD	Hold +72.3% avg upside 13 analysts	$8.00 21.41% Downside	+17.3%
IDYA IDEAYA Biosciences	May 29, 2026	BUY	Strong Buy +55.2% avg upside 29 analysts	$66.00 111.41% Upside	+6.1%
TVTX Travere Therapeutics	May 29, 2026	BUY	Strong Buy -16.0% avg upside 22 analysts	$53.00 3.95% Downside	+10.3%
RARE Ultragenyx Pharmaceutical	May 22, 2026	BUY	Strong Buy +142.1% avg upside 36 analysts	$72.00 162.42% Upside	·
TRAX First Tracks Biotherapeutics Inc	May 22, 2026	BUY	Strong Buy +113.2% avg upside 7 analysts	$30.00 72.23% Upside	·
MAZE Maze Therapeutics, Inc.	May 22, 2026	BUY	Strong Buy +145.3% avg upside 12 analysts	$53.00 106.41% Upside	-3.6%
VERA Vera Therapeutics	May 22, 2026	BUY	Strong Buy +91.0% avg upside 19 analysts	$86.00 145.06% Upside	-5.1%
SLDB Solid Biosciences	May 22, 2026	BUY	Strong Buy +90.3% avg upside 23 analysts	$11.00 32.05% Upside	·
ZLAB Zai Lab	May 22, 2026	BUY	Strong Buy +224.1% avg upside 13 analysts	$27.00 48.56% Upside	-8.3%
ANAB AnaptysBio	May 22, 2026	BUY	Strong Buy +26.1% avg upside 26 analysts	$70.00 21.78% Upside	-3.5%
SRPT Sarepta Therapeutics	May 18, 2026	HOLD	Buy +244.5% avg upside 49 analysts	$19.00 8.33% Upside	-7.4%
ERAS Erasca	May 13, 2026	BUY	Strong Buy +39.0% avg upside 14 analysts	$23.00 68.21% Upside	+33.7%
KOD Kodiak Sciences	May 13, 2026	BUY	Buy +37.3% avg upside 11 analysts	$56.00 55.00% Upside	-9.8%
BBIO BridgeBio Pharma	May 12, 2026	BUY	Strong Buy +38.7% avg upside 34 analysts	$100.00 50.99% Upside	+2.2%
NBIX Neurocrine	May 08, 2026	BUY	Strong Buy +7.8% avg upside 37 analysts	$185.00 16.85% Upside	+4.9%
KNSA Kiniksa Pharmaceuticals	May 04, 2026	BUY	Strong Buy -0.2% avg upside 11 analysts	$72.00 30.66% Upside	-9.2%
ORIC Oric Pharmaceuticals	Apr 13, 2026	BUY	Strong Buy +180.3% avg upside 19 analysts	—	-20.5%
PROK ProKidney	Mar 25, 2026	HOLD	Buy +260.7% avg upside 12 analysts	—	-0.5%
BMEA Biomea Fusion	Mar 24, 2026	SELL	Strong Buy +1037.0% avg upside 15 analysts	—	-29.2%
ANNX Annexon Biosciences	Mar 18, 2026	BUY	Strong Buy +181.2% avg upside 13 analysts	—	-5.5%
CTMX CytomX Therapeutics	Mar 16, 2026	BUY	Strong Buy +269.6% avg upside 21 analysts	$12.00 306.70% Upside	-55.4%
SNDX Syndax Pharmaceuticals	Mar 09, 2026	BUY	Strong Buy +88.8% avg upside 27 analysts	$45.00 136.81% Upside	-23.3%
AGMB AgomAb Therapeutics NV ADR	Mar 03, 2026	BUY	Strong Buy +138.5% avg upside 3 analysts	$32.00 191.49% Upside	·
ENTA Enanta Pharmaceuticals	Mar 03, 2026	BUY	Buy +159.2% avg upside 17 analysts	$19.00 50.12% Upside	-14.1%
VOR Vor Biopharma	Dec 18, 2025	BUY	Buy +199.3% avg upside 17 analysts	$40.00 176.03% Upside	+9.9%
NVAX Novavax	Nov 18, 2025	SELL	Buy +154.1% avg upside 20 analysts	$6.00 34.30% Downside	-35.2%
RLYB Rallybio	May 14, 2024	HOLD	Buy +14.8% avg upside 8 analysts	—	-83.2%
ALNY Alnylam Pharma	Feb 01, 2024	HOLD	Strong Buy +23.6% avg upside 51 analysts	$170.00 38.86% Downside	+55.1%
KLRS Kalaris Therapeutics	Dec 22, 2023	SELL	Buy +170.1% avg upside 13 analysts	—	+47.2%
ATRA Atara Biotherapeutics	Aug 15, 2022	HOLD	Buy +79.6% avg upside 18 analysts	$5.00 50.42% Downside	-65.5%
BCAB BioAtla	May 11, 2022	BUY	Strong Buy +2518.3% avg upside 13 analysts	$26.00 611.25% Upside	+47.9%
CYTK Cytokinetics	May 11, 2022	BUY	Strong Buy +8.9% avg upside 36 analysts	$64.00 18.78% Downside	+2.5%
AGIO Agios Pharma	May 10, 2022	HOLD	Strong Buy +73.2% avg upside 29 analysts	$48.00 40.54% Upside	+18.4%
SYRE Spyre Therapeutics	May 10, 2022	BUY	Strong Buy -15.4% avg upside 23 analysts	$8.00 90.84% Downside	·
PTGX Protagonist Therapeutics	May 06, 2022	BUY	Strong Buy -22.1% avg upside 19 analysts	$45.00 60.18% Downside	+172.6%
PASG Passage Bio	Mar 08, 2022	HOLD	Buy +214.0% avg upside 14 analysts	—	-50.7%
TBPH Theravance Biopharma	Feb 25, 2022	HOLD	Buy +12.2% avg upside 18 analysts	$13.00 21.61% Downside	-3.6%
SRRK Scholar Rock Holding	Nov 12, 2021	BUY	Strong Buy +20.1% avg upside 23 analysts	$55.00 16.27% Upside	-75.8%
VIR Vir Biotechnology	Oct 25, 2021	HOLD	Strong Buy +185.4% avg upside 16 analysts	$37.00 303.94% Upside	-46.9%
INFIQ Infinity Pharmaceuticals	Aug 05, 2021	BUY	Buy +647142757.1% avg upside 8 analysts	$6.00 599999900.06% Upside	-73.3%
KRRO Korro Bio	Mar 25, 2021	SELL	Strong Buy +108.3% avg upside 19 analysts	$10.00 23.04% Downside	+76.1%
DYN Dyne Therapeutics	Oct 12, 2020	BUY	Strong Buy +92.7% avg upside 29 analysts	$27.00 36.26% Upside	-22.1%
IFRX InflaRx	Jun 05, 2019	SELL	Buy +390.4% avg upside 11 analysts	—	-144.8%
RIGL Rigel	Mar 01, 2019	BUY	Strong Buy -27.5% avg upside 17 analysts	$6.00 81.78% Downside	-5.4%
CLSDQ Clearside Biomedical	Nov 05, 2018	SELL	Hold +10264.6% avg upside 10 analysts	$8.00 2861.39% Upside	+38.6%
PTCT PTC Therapeutics	Nov 16, 2017	HOLD	Buy -1.5% avg upside 29 analysts	—	+113.6%
PTC PTC	Sep 29, 2017	HOLD	Strong Buy +32.6% avg upside 31 analysts	—	+88.7%
IRWD Ironwood Pharma	Jul 21, 2017	HOLD	Hold +235.6% avg upside 23 analysts	$19.00 436.71% Upside	+16.3%
MESO Mesoblast	Jun 15, 2016	HOLD	Strong Buy +72.5% avg upside 14 analysts	—	+84.4%

🔒 49 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Anupam Rama — Frequently Asked Questions

How accurate are Anupam Rama's stock ratings?

Based on the calls 13Foresight could measure, about 47% of Anupam's ratings were profitable over a one-year hold, with an average return of +1.8% per rating, or -5.5% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Anupam ranked on 13Foresight?

Anupam Rama is currently ranked #2198 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Anupam cover?

Anupam most recently has ratings on CAMP, NUVL, OLMA, FULC, COGT, REPL, IDYA, TVTX, RARE, TRAX, MAZE, VERA and 42 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!